Safety and efficacy study of lung cancer stem cell vaccine.
In this trial, lung cancer stem cells (CSCs) were separated and cultured to produce a vaccine; its safety and efficacy were prospectively evaluated in low-, medium-, and high-dose groups. Between February and September 2014, we enrolled 90 patients who met the enrollment criteria and assigned them to three groups (n = 30). Throughout the trial, injection site reaction was the most common reaction (63 %), and fever was least common (16 %); however, there was no difference among the three groups. When the immune responses pre- and post-vaccination were compared, we found that the CSC-nonspecific and CSC-specific responses were both significantly enhanced in the medium- and high-dose groups. This study is the first clinical trial of a lung CSC vaccine and preliminarily proves its safety and efficacy.
Fuda Cancer Hospital, Jinan University School of Medicine, Guangzhou, China.
Mao
M
Lin
Shu-Ying
SY
Li
Ke-Cheng
KC
Xu
Zheng-Ping
ZP
Liu
Feng
F
Mu
Yuan-Ying
YY
Yuan
Xiao-Hua
XH
Wang
Ji-Bing
JB
Chen
Qiao
Q
Li
D019496:Cancer Vaccines / Q000009:adverse effects / Q000627:therapeutic use*; D016207:Cytokines / Q000276:immunology; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000276:immunology; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D008875:Middle Aged; D014411:Neoplastic Stem Cells; D016896:Treatment Outcome
D019496:Cancer Vaccines; D016207:Cytokines